600535.SS SHH
Tasly Pharmaceutical Group Co., Ltd
1W: +0.4%
1M: -4.6%
3M: +1.7%
YTD: -6.4%
1Y: -12.0%
3Y: +10.8%
5Y: +19.4%
¥14.00 ($2.09)
+0.26 (+1.89%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$1.4B
-29.3% ▼
5Y CAGR: -4.5%
Capital Expenditures
$381M
+32.5% ▲
5Y CAGR: -1.4%
Free Cash Flow
$1.0B
-28.0% ▼
5Y CAGR: -5.5%
Dividends Paid
$613M
+41.2% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$598M
+143.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $2.4B | -$341M | $1.0B | $859M | $1.1B |
| Depreciation & Amort. | $488M | $517M | $505M | $496M | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | $1.3B | $522M | $642M | $218M | -$187M |
| Other Non-Cash Items | -$1.4B | $1.6B | $412M | $441M | $507M |
| Operating Cash Flow | $2.8B | $2.3B | $2.6B | $2.0B | $1.4B |
| — Investing Activities — | |||||
| Capital Expenditures | -$572M | -$403M | -$669M | -$565M | $0 |
| Acquisitions (Net) | $277M | -$9M | $0 | $0 | $0 |
| Investment Purchases | -$1.5B | -$3.9B | -$1.8B | -$7.5B | $0 |
| Investment Sales | $1.7B | $3.0B | $1.6B | $7.3B | $0 |
| Other Investing | $69M | $6M | -$1.3B | -$136M | -$446M |
| Investing Cash Flow | -$43M | -$1.3B | -$2.1B | -$941M | -$446M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1.3B | $400M | $555M | -$1.1B | -$625M |
| Stock Repurchased | -$56M | -$61M | $0 | $0 | $0 |
| Dividends Paid | -$496M | -$493M | -$493M | -$1.0B | -$613M |
| Other Financing | -$536M | -$22M | -$1.3B | -$352M | $868M |
| Financing Cash Flow | -$2.5B | -$236M | -$1.2B | -$2.5B | -$370M |
| Net Change in Cash | $277M | $814M | -$731M | -$1.4B | $598M |
| Cash End of Period | $2.1B | $2.9B | $2.2B | $817M | $1.4B |
| Free Cash Flow | $2.2B | $1.9B | $1.9B | $1.4B | $1.0B |